The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
BUSINESS
Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
Eisai’s operating profit tumbled over 80% in April-December 2022 in a retreat from a one-off gain associated with its antibody-drug conjugate (ADC) alliance with Bristol Myers Squibb booked a year earlier. According to the company’s nine-month earnings released on February…
To read the full story
Related Article
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
May 16, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai’s Q1 Operating Profit Drops 86% on Upfront Payment Receipt in FY2021
August 8, 2022
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Eisai Seeks to File Lecanemab in Japan, US, Europe in FY2022: CEO
May 16, 2022
- Eisai Slashes FY2021 Profit Outlook on Aduhelm Woes
May 9, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
- Eisai’s Q1 Sales Jump 20% on Growth of 4 Global Brands
August 5, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Eisai’s April-December Profits Slip on Aggressive Investments
February 4, 2021
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
- Eisai Shakes Off Price Cut, Coronavirus Blow with Lenvima Growth in Q1
August 4, 2020
BUSINESS
- Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
- Tecentriq-Avastin Yields Positive Data on HCC: China/Japan PIII
May 23, 2025
- Meiji, Sandoz Tie-Up to Secure Stable Supply of Antibiotic Intermediates
May 23, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
- Alloy Japan Now Up and Running to Deliver iCAR-T for Cancer Therapy Development
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…